Mark L. Cunningham - Concepedia

Concepedia

Author

Mark L. Cunningham

London School of Hygiene & Tropical Medicine

Also Known As

Mark Cunningham, Mark L Cunningham, Mark L. CUNNINGHAM, Mark L. Cunningham

35

Publications

2.3K

Citations

25

H-Index

52

Concepts

All Affiliations

London School of Hygiene & Tropical Medicine Arcturus Therapeutics (United States)University of London Washington University in St. Louis Lawrence Livermore National Laboratory

ML

About

Mark L. Cunningham is an author at London School of Hygiene & Tropical Medicine specializing in medicine, pharmacology, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	17	1.4K
2	Natural Sciences	11	12	1K
3	Biochemistry	11	11	997
4	Health Sciences	2	2	76
5	Biology	1	1	120

Mark L. Cunningham

×

26

Publications

2.3K

Citations

25

H-Index

	Year	Citations
Dual Action of Antimonial Drugs on Thiol Redox Metabolism in the Human Pathogen Leishmania donovani Susan Wyllie, Mark L. Cunningham, Alan H. Fairlamb Journal of Biological Chemistry	2004	305
Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors Charles S. Bond, Yihong Zhang, Matthew Berriman, Structure Crystal StructureBiochemistryBiomolecular Structure PredictionNatural SciencesAfrican Trypanosomiasis	1999	201
Down-regulation of <i>Leishmania donovani</i> trypanothione reductase by heterologous expression of a trans-dominant mutant homologue: Effect on parasite intracellular survival Jorge Tovar, Mark L. Cunningham, Aden C. Smith, Proceedings of the National Academy of Sciences	1998	169
Trypanothione Reductase from Leishmania donovani. Purification, Characterisation and Inhibition by Trivalent Antimonials Mark L. Cunningham, Alan H. Fairlamb European Journal of Biochemistry Glutathione DisulfideAntiparasitic AgentMolecular BiologyChemical BiologyVisceral Leishmaniasis	1995	122
Regulation of Differentiation to the Infective Stage of the Protozoan Parasite <i>Leishmania major</i> by Tetrahydrobiopterin Mark L. Cunningham, Richard G. Titus, Salvatore J. Turco, Science BiologyLeishmania DifferentiationInfectious CycleBiosynthesisInfective Stage	2001	120
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity Leslie W. Tari, Michael Trzoss, Daniel C. Bensen, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryDrug TargetDna Gyrase BBiochemistryNatural Sciences	2012	115
Mechanism of inhibition of trypanothione reductase and glutathione reductase by trivalent organic arsenicals Mark L. Cunningham, Marketa Zvelebil, Alan H. Fairlamb European Journal of Biochemistry	1994	103
Tricyclic GyrB/ParE (TriBE) Inhibitors: A New Class of Broad-Spectrum Dual-Targeting Antibacterial Agents Leslie W. Tari, Xiaoming Li, Michael Trzoss, PLoS ONE Topoisomerase ComplexesImportant PathogensMolecular BiologyAntimicrobial ChemotherapyChemical Biology	2013	103
Characterisation of melarsen-resistant Trypanosoma brucei brucei with respect to cross-resistance to other drugs and trypanothione metabolism Alan H. Fairlamb, Nicola S. Carter, Mark L. Cunningham, Molecular and Biochemical Parasitology Antiparasitic AgentMedicineOther DrugsTrypanothione MetabolismParasitic Protozoa	1992	100
Pteridine salvage throughout the Leishmania infectious cycle: implications for antifolate chemotherapy Mark L. Cunningham, Stephen M. Beverley Molecular and Biochemical Parasitology Antifolate ChemotherapyAntiparasitic AgentMedicineParasitic ProtozoaLeishmania Infectious Cycle	2001	100

Page 1